MetaCap

Elicio Therapeutics (ELTX) vs OS Therapies (OSTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OS Therapies (OSTX) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 53.0% versus a loss of 82.8%. OS Therapies is the larger company by market cap ($42.0 million vs $41.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELTX-82.84%OSTX-53.04%
+84%-4%-91%
Nov 21, 20251 yearNov 20, 2026
ELTX-71.34%OSTX-79.92%
+207%+56%-95%
Jul 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELTX versus OSTX key metrics
MetricELTXOSTX
Share price$1.45$0.803
Market cap$41.05M$42.00M
1-day change-3.33%-2.12%
YTD return-81.78%-42.64%
1-year return-82.84%-53.04%
5-year return-96.13%—
Forward P/E—2.29
EPS (TTM)$-1.81$-1.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-39.57M$-28.75M
52-week high$16.00$2.25
52-week low$1.25$0.58
Distance from 52-week high-90.94%-64.31%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+842.76%+958.53%
Average volume324.71K722.66K
Shares outstanding28.31M52.30M
Employees334
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OSTX has outperformed ELTX by 29.8 percentage points over the past year.

About Elicio Therapeutics

ELTX stock →

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About OS Therapies

OSTX stock →

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

ELTX vs OSTX FAQ

Which is bigger, Elicio Therapeutics or OS Therapies?

OS Therapies (OSTX) is larger, with a market capitalization of $42.00M compared with $41.05M for Elicio Therapeutics (ELTX).

Which stock has performed better over the past year, ELTX or OSTX?

OSTX returned -53.04% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.

Are Elicio Therapeutics and OS Therapies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons